ArticleJournal of gastrointestinal oncology2012
Molecular pathology of pancreatic neuroendocrine tumors.
Article in Journal of gastrointestinal oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Bilateral breast metastases as the first manifestation of an occult pancreatic neuroendocrine tumor.Radiology case reports · 2021Article
- Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer.Scientific reports · 2021Article
- Review
- Pancreatic Neuroendocrine Tumor in a Young Child With Tuberous Sclerosis Complex 1.Journal of the Endocrine Society · 2019Article
- Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas.Nature communications · 2017Article
- Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo.Pancreas · 2017Article
- Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.Cancer biology & therapy · 2016Article
- Von Hippel-Lindau Disease.Journal of pediatric genetics · 2016Review
- Co-existence of insulinoma and diabetes: A case report.Oncology letters · 2014Article
- Clinical and pathological features of non-functional neuroendocrine tumors of pancreas: a report from iran.Middle East journal of digestive diseases · 2014Article
- Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Giant pancreatic insulinoma. The bigger the worse? Report of two cases and literature review.International journal of surgery case reports · 2013Article
- Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.Best practice & research. Clinical gastroenterology · 2012Review
- Pathologic aspects of tumors of gastrointestinal tract in the era of personalized medicine.Journal of gastrointestinal oncology · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Pancreatic endocrine tumors (PETs) are rare neoplasms which account for 1% to 2% of all pancreatic malignancies. The diagnostic, grading and prognostic criteria for PETs have been controversial in surgical pathology and clinical medicine. The newly updated 2010 WHO classification introduced in clinical practice will give more insight into genetic and molecular changes related to PET subtypes. These neoplasms can be graded into 1 of 3 tiers, based on histologic characteristics in likeness to epithelial neuroendocrine tumors in other anatomic sites. Most PETs are sporadic, however, some of them, may occur as part of familial tumors (inherited syndromes) such as multiple endocrine neoplasia type 1 (MEN1 syndrome), von Hippel-Lindau disease (VHL), neurofibromatosis type 1 (NF-1), and tuberous sclerosis (TSC). In sporadic endocrine pancreatic tumors, losses of chromosome 1 and 11q as well as gain on 9q appear to be early events in the development of pancreatic tumors. Multiple genetic defects may accumulate with time and result in pancreatic neuroendocrine tumor progression and malignancy. Although PETs may be similar or identical in histologic appearance to neuroendocrine tumors of the gastrointestinal tract, differences in their underlying biology and likely differences in response to therapeutic agents suggest that they should be treated and investigated as a distinct entity. The correlation of PI3K/Akt/mTOR pathway in the pathogenesis of PETs has been reported, and clinical trials data of mTOR inhibitors is promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.